NCT04752059View on ClinicalTrials.gov

Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

May 1, 2023

Study Completion Date

May 1, 2023

Conditions
Breast Cancer Stage IV
Interventions
DRUG

Trastuzumab deruxtecan

Trastuzumab-deruxtecan 5.4 mg/kg body weight i.v. on day 1 once every three weeks until progression or death

Trial Locations (1)

1090

AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology, Vienna

Sponsors

Collaborators (1)

Daiichi Sankyo
All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

Medical University of Vienna

OTHER